SCHEMBL1811299

SCHEMBL1811299

COC(=O)c1ccc(OC)c(OCC(=O)c2cccc(C)c2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 2/20 0.66
WNT3A P56704 2/20 0.66
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
POLB P06746 2/20 0.56
MAPT P10636 6/20 0.56
TSHR P16473 2/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
BLM P54132 1/20 0.55
ACHE P22303 2/20 0.50
HIF1A Q16665 1/20 0.50
EPAS1 Q99814 1/20 0.50
GAA P10253 2/20 0.48
LMNA P02545 2/20 0.48
ALDH1A1 P00352 2/20 0.47
HSD17B10 Q99714 1/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15969220 0.80 CTNNB1 (1.00) CTNNB1WNT3ANPC1RAB9APOLB
SCHEMBL29115858 0.80 CTNNB1 (0.66) CTNNB1WNT3ANPC1RAB9APOLB
SCHEMBL30697348 0.80 CTNNB1 (0.66) CTNNB1WNT3ANPC1RAB9APOLB
SCHEMBL19632865 0.79 L3MBTL1 (0.57) CTNNB1WNT3ANPC1RAB9APOLB
SCHEMBL1561511 0.78 LMNA (0.59) CTNNB1WNT3ANPC1RAB9APOLB
SCHEMBL40429 0.78 GPR17 (0.65) CTNNB1RAB9APOLBMAPTTSHR
SCHEMBL29534771 0.78 GPR17 (0.65) CTNNB1RAB9APOLBMAPTTSHR
SCHEMBL28289702 0.78 GPR17 (0.65) CTNNB1RAB9APOLBMAPTTSHR
SCHEMBL31150639 0.77 HIF1A (0.67) CTNNB1WNT3ANPC1RAB9APOLB
SCHEMBL15954474 0.77 HIF1A (0.67) CTNNB1WNT3ANPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2496556-B1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2018-12-26 EP disclosed
US-9018383-B2 Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2015-04-28 US disclosed
US-20140088158-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2014-03-27 US disclosed
US-8618304-B2 Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2013-12-31 US disclosed
US-20120264790-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-10-18 US disclosed
EP-2496556-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-09-12 EP disclosed
WO-2011053948-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264790-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS LPAR2, LIPG, EDF1 CTNNB1 3969/4885WNT3A 2680/4885NPC1 2159/4885
US-20140088158-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS LPAR2, LIPG, EDF1 CTNNB1 3969/4885WNT3A 2680/4885NPC1 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.